Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Christophe Borg

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

C. Borg1, L. Spehner2, M. Kroemer3, S. Kim1, M. Jary1, A. Vienot4, E. Klajer5, M. Ramseyer2, O. Adotevi6, Y. Godet7, T. Andre8, B. Buecher9, E. FRANCOIS10, R. LOYON2

Author affiliations

  • 1 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Thérapeutique Immuno-moléculaire Des Cancers, UMR1098, 25020 - Besançon/FR
  • 3 Pharmacy, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 4 Medical Oncology, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 5 Medical Oncolgy, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 6 Immunomolecular Therapy Of Cancer, UMR1098, 25020 - Besançon/FR
  • 7 Thérapeutique Immuno Moléculaire Des Cancers, UMR1098, 25020 - Besançon/FR
  • 8 Medical Oncology, Hopital Saint-Antoine, 75571 - Paris/FR
  • 9 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 10 Medical Oncology, Centre Antoine Lacassagne, 06189 - Nice Cedex/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3597

Background

Anal squamous cell carcinoma (SCCA) is associated with E6 and E7 oncoproteins encoded by human papillomavirus (HPV) 16. Addition of Docetaxel to 5-Fluorouracil plus Cisplatin (DCF) induces favorable disease control and complete remission rate in recent clinical trials. Taking this observation into account, we decided to analyze the impact of DCF chemotherapy on adaptive immunity and immunosuppressive cells in SCCA.

Methods

Peripheral blood mononuclear cells from healthy donors and SCCA patients included in Epitopes-HPV01 and 02 studies were analyzed. The presence of T-cell responses after short term T-cell stimulation against HPV16-E6/E7 and TERT-antigens was measured by IFNγ-ELISpot. Immune checkpoint expression and immunosuppressive cells were monitored by flow cytometry.

Results

We first observed an enhanced HPV-specific T-cell response following DCF chemotherapy. Our investigations also suggest that TERT might be a relevant antigen in HPV-driven cancers. TERT-restricted CD4 Th1 were correlated to E6 responses and also enhanced following DCF treatment of SCCA patients. The distribution of T-cell exhaustion markers on peripheral T lymphocytes unraveled a drop of CD226 expression and the emergence of CD226-TIGIT+ T-cell subset. Monocytic-myeloid-derived-suppressor cells (M-MDSC) and regulatory T-cell (Treg) rates were increased. Treg levels and T-cell exhaustion markers did not influence clinical outcomes and frequencies of specific immune responses. M-MDSC levels monitored after DCF chemotherapy were correlated with progression free survival and antigen-specific T-cell response intensity and diversity.

Conclusions

DCF chemotherapy did not impair antigen-specific T-cell responses, supporting the potential interest to combine DCF chemotherapy with immunotherapies. Moreover, our study identifies post-therapy M-MDSC as a prognostic factor in SCCA patients.

Clinical trial identification

Epitopes-HPV01: NCT01845779 Epitopes-HPV02: NCT02402842.

Editorial acknowledgement

Legal entity responsible for the study

University Hospital of Besançon.

Funding

Besancon University Hospital, Ligue Contre le cancer Grand-Est and Association Nationale de la Recherche et de la Technologie.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.